Publications by authors named "Shivanand Gamnagatti"
Introduction: Metallic foreign body reactions are observed many times, usually in the early periods. However, late presentations are often uncommon. Management of these foreign bodies varies from a military setting to a civilian setting where saving a patient's life is the priority.
View Article and Find Full Text PDFComparison of Denosumab and Zoledronic acid as neoadjuvant therapy in patients with giant cell tumor of bone.
J Orthop Surg (Hong Kong)
October 2021
Article Synopsis
- The study compares the effectiveness of Zoledronic acid and Denosumab in reducing lesions and aiding surgery for Giant Cell Tumors (GCT) in a neo-adjuvant context.
- It involved analyzing the outcomes of 39 patients who were treated with either medication, focusing on factors like tumor reduction, surgery facilitation, complications, costs, recurrence rates, and overall success.
- Results showed no significant differences in outcomes between the two drugs; however, Zoledronic acid was found to be cheaper and had slightly lower recurrence rates, suggesting it may be a more cost-effective option, warranting further research.
Prediction of chemotherapy response by PET-CT in osteosarcoma: correlation with histologic necrosis.
J Pediatr Hematol Oncol
October 2011
Background: The current standard for neoadjuvant chemotherapy (NACT) response evaluation in osteosarcoma is histopathologic necrosis (HN). However, it is accessible only after NACT completion and may get affected by confounding factors. Thus, noninvasive surrogate such as (18)Fluorine-Fluorodeoxyglucose-positron emission tomography-computerized tomography (PET-CT) scan would be useful to individualize therapy.
View Article and Find Full Text PDFBackground: Histological necrosis, the current standard for response evaluation in osteosarcoma, is attainable after neoadjuvant chemotherapy.
Objective: To establish the role of surrogate markers of response prediction and evaluation using MRI in the early phases of the disease.
Materials And Methods: Thirty-one treatment-naïve osteosarcoma patients received three cycles of neoadjuvant chemotherapy followed by surgery during 2006-2008.
Background: The vascular endothelial growth factor (VEGF) pathway is the key regulator of angiogenesis. In osteosarcoma baseline VEGF is of proven prognostic value but prognostic potential of post-NACT VEGF expression is largely unexplored.
Procedure: Treatment naive patients with osteosarcoma were subjected to initial staging workup followed by three cycles of neoadjuvant chemotherapy (NACT) and surgery; resected tumors were assessed for histological necrosis by Huvos grading.